Werewolf Therapeutics, Inc.
HOWLNASDAQHealthcare● Active
$0.37
$-0.01(-1.86%)
Market Cap$18214081
P/E Ratio—
52W High$2.38
52W Low$0.37
Werewolf Therapeutics, Inc. (HOWL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HOWL · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.02B | $0.02B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.00B | $0.02B | $0.01B | $0.00B |
| Gross Margin %(computed) | — | 3.77% | 91.15% | 84.70% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.04B | $0.06B | $0.04B | $0.05B | $0.04B |
| G&A Expenses | $0.02B | $0.02B | $0.02B | $0.02B | $0.01B |
| Total Operating Expenses | $0.06B | $0.07B | $0.06B | $0.07B | $0.05B |
| Operating Income | ($0.06B) | ($0.07B) | ($0.04B) | ($0.06B) | ($0.05B) |
| Operating Margin %(computed) | — | — | -203.09% | -341.78% | — |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.06B) | ($0.07B) | ($0.04B) | ($0.05B) | ($0.05B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.06B) | ($0.07B) | ($0.04B) | ($0.05B) | ($0.05B) |
| Net Margin %(computed) | — | — | -187.37% | -328.09% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.32 | $-1.63 | $-1.05 | $-1.86 | $-10.94 |
| Wtd Avg Shares | 0.05B | 0.04B | 0.04B | 0.03B | 0.02B |
| EBITDA | ($0.06B) | ($0.06B) | ($0.03B) | ($0.05B) | ($0.05B) |
| EBITDA Margin %(computed) | — | — | -162.79% | -312.79% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Werewolf Therapeutics, Inc. data
About Werewolf Therapeutics, Inc. (HOWL) Income Statement
Werewolf Therapeutics, Inc. (HOWL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, HOWL reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.06B) — a net profit margin of —.
Frequently asked questions
HOWL · 4 questionsWerewolf Therapeutics, Inc. (HOWL) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
HOWL revenueHOWL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09